Evidence map›Paper›PMID 34877631›Full record

ArticleAdvances in therapy2022

Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease.

Juliana Setyawan, Fan Mu, Miriam L Zichlin, Emma Billmyer, Nathaniel Downes, Hongbo Yang, Nassir Azimi, Vibeke Strand, Andres Yarur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juliana SetyawanArena Pharmaceuticals, Inc., San Diego, CA, USA.
Fan MuAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA. Fan.Mu@analysisgroup.com.ORCID http://orcid.org/0000-0003-0252-0387
Miriam L ZichlinAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Emma BillmyerAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Nathaniel DownesAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Hongbo YangAnalysis Group Inc., 111 Huntington Avenue, 14th Floor, Boston, MA, 02199, USA.
Nassir AzimiSharp Grossmont Hospital, La Mesa, CA, USA.
Vibeke StrandDivision of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, USA.
Andres YarurDivision of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInflammatory bowel disease (IBD) is associated with greater risk of thromboembolic events (TEs) due to the link between systemic inflammation and hypercoagulability. This study assessed the rates of TEs among patients with IBD versus patients without immune-mediated disease (IMD) and the cost of TEs among patients with IBD in the United States.

methodsThis study used the IBM MarketScan

resultsThere were 34,687 matched pairs included in the rates of TE analyses. Compared to patients without IMD, patients with IBD had greater rates of DVT (adjusted IRR [95% confidence interval] 2.44 [2.00, 2.99]; p < 0.01) and PE (1.90 [1.42, 2.54]; p < 0.01). Increased rates were not observed for IS and MI. There were 1885 matched pairs included in the cost of TE analyses. Patients with IBD with TEs incurred greater healthcare costs over 30 days and 1 year versus patients without TEs (adjusted total cost difference: 30 days $20,784; 1 year $44,630; p < 0.01 for both).

conclusionsPatients with IBD experienced greater rates of DVT and PE compared to patients without IMD; this elevated risk was associated with a substantial economic burden.

Indexed as

Inflammatory Bowel DiseasesThromboembolismVenous ThrombosisAgedHealth Care CostsHumansMedicareUnited StatesEconomic burdenHealthcare costsInflammatory bowel diseaseThromboembolic events

Identifiers

PMID34877631
PMCPMC8799565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.